<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03678493</url>
  </required_header>
  <id_info>
    <org_study_id>2017LS170</org_study_id>
    <secondary_id>MT2018-01</secondary_id>
    <nct_id>NCT03678493</nct_id>
  </id_info>
  <brief_title>A Study of FMT in Patients With AML Allo HSCT in Recipients</brief_title>
  <official_title>A Randomized Placebo-Controlled Clinical Trial of Fecal Microbiota Transplantation in Patients With Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplantation Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled clinical trial of Fecal Microbiota
      Transplant (FMT) in 2 independent cohorts (60 acute myeloid leukemia patients undergoing
      intensive chemotherapy and 60 Allo-HCT patients). Participants in each cohort will be
      randomized in a 2:1 ratio to receive up to 3 treatments of FMT vs. placebo after each
      exposure to antibacterial antibiotics until 3 months after randomization.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    temporarily closed to accrual
  </why_stopped>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of FMT in AML patients and allo-HCT recipients - Incidence of infections</measure>
    <time_frame>4 Months</time_frame>
    <description>Incidence of infections infections until 4 months after the first intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of FMT Engraftment</measure>
    <time_frame>2 Weeks post-FMT</time_frame>
    <description>Rate of FMT Engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of FMT Engraftment</measure>
    <time_frame>4 Weeks post-FMT</time_frame>
    <description>Rate of FMT Engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute grade II-IV GVHD</measure>
    <time_frame>Day 180 post-HCT</time_frame>
    <description>Allo-HCT cohort: incidence of acute grade II-IV GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of BSI of suspected gut origin</measure>
    <time_frame>1 week post-FMT</time_frame>
    <description>Incidence of BSI of suspected gut origin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Bacterial Infections</measure>
    <time_frame>4 Months post-intervention</time_frame>
    <description>Incidence of Bacterial Infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Viral Infections</measure>
    <time_frame>4 Months post-intervention</time_frame>
    <description>Incidence of Viral Infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Fungal Infections</measure>
    <time_frame>4 Months post-intervention</time_frame>
    <description>Incidence of Fungal Infections</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Allogeneic Hematopoietic Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>AML Patients undergoing Intensive Chemothera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AML Patients undergoing Intensive Chemotherapy Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AML Patients undergoing Allo-HCT Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AML Patients undergoing Allo-HCT Patients Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplant (FMT)</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>AML Patients undergoing Allo-HCT Patients</arm_group_label>
    <arm_group_label>AML Patients undergoing Intensive Chemothera</arm_group_label>
    <other_name>FMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Capsule</description>
    <arm_group_label>AML Patients undergoing Allo-HCT Patients Control</arm_group_label>
    <arm_group_label>AML Patients undergoing Intensive Chemotherapy Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ageâ‰¥ 18 years

          -  Cohort A: Patients undergoing intensive induction chemotherapy for acute myeloid
             leukemia (AML; newly diagnosed or relapsed/refractory).

             * Any intensive regimen with planned ~4 weeks of inpatient stay

          -  Cohort B: Allo-HCT patients

             * Any allogeneic transplant regimen with planned GVHD prophylaxis containing generic
             IV Mycophenolate Mofetil (MMF) and tacrolimus (Tac)

          -  Sexually active females of childbearing potential and males with partners of
             child-bearing potential must agree to use adequate birth control until at least six
             months post-FMT/placebo

          -  Voluntary written consent signed before performance of any study-related procedure not
             part of normal medical care

        Exclusion Criteria:

          -  Planned continuation of antibacterial antibiotics after the first neutrophil recovery
             (ANC &gt; 1,000)

          -  Patients who are currently receiving or recently received (within 28 days) other
             investigational agents.

          -  Pregnant or breast feeding. The FDA has not classified this agent into a specified
             pregnancy category. Females of childbearing potential must have a blood test or urine
             study within 14 days prior to registration to rule out pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armin Rashidi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, Division of Hematology, Oncology and Transplantation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Allo-HCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

